Literature DB >> 9605774

Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines.

S E Patton1, M L Martin, L L Nelsen, X Fang, G B Mills, R C Bast, M C Ostrowski.   

Abstract

The activation status of the ras pathway was studied in eight ovarian tumor cell lines. Three biochemical parameters indicative of ras activation were tested: (a) the ratio of the ras-GTP:ras-GDP complex; (b) the activity of mitogen-activated protein kinases p42/p44; and (c) ets-2 phosphorylation at position threonine 72, a mitogen-activated protein kinase phosphorylation site in vivo. Four of the ovarian tumor cell lines had an activated ras pathway by these three parameters, whereas only one of these contained a mutated ras gene. In addition, ras/ets-2 responsive genes such as the urokinase plasminogen activator (uPA) were activated in these four cell lines. Transient transfection assays indicated that the compound ets-AP1 oncogene responsive enhancer present in the uPA gene was the target of ras signaling in ovarian tumor cells and that the combination of activated ras and ets-2 could superactivate the uPA enhancer element. Coexpression of the dominant-negative ras-Asn17 cDNA gene abrogated activity of this uPA element in ovarian tumor cells. These data indicate that ets-2 is a nuclear target of ras action in ovarian tumor cell lines and that ras signaling pathways may be activated in ovarian cancer by mechanisms independent of direct genetic damage to ras genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605774

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model.

Authors:  Travis Young; Fang Mei; Jinsong Liu; Robert C Bast; Alexander Kurosky; Xiaodong Cheng
Journal:  Oncogene       Date:  2005-09-08       Impact factor: 9.867

2.  Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.

Authors:  Fuminori Teraishi; Wei Guo; Lidong Zhang; Fengqing Dong; John J Davis; Takehiko Sasazuki; Senji Shirasawa; Jinsong Liu; Bingliang Fang
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

3.  Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.

Authors:  Charles E Foulds; Mary L Nelson; Adam G Blaszczak; Barbara J Graves
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

4.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Authors:  Chaoyang Sun; Yong Fang; Jun Yin; Jian Chen; Zhenlin Ju; Dong Zhang; Xiaohua Chen; Christopher P Vellano; Kang Jin Jeong; Patrick Kwok-Shing Ng; Agda Karina B Eterovic; Neil H Bhola; Yiling Lu; Shannon N Westin; Jennifer R Grandis; Shiaw-Yih Lin; Kenneth L Scott; Guang Peng; Joan Brugge; Gordon B Mills
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

5.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Authors:  Y Yu; F Xu; H Peng; X Fang; S Zhao; Y Li; B Cuevas; W L Kuo; J W Gray; M Siciliano; G B Mills; R C Bast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

6.  Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma.

Authors:  Takatoshi Yamamoto; Takatoshi Ohno; Kazuhiko Wakahara; Akihito Nagano; Gou Kawai; Mitsuru Saitou; Iori Takigami; Aya Matsuhashi; Kazunari Yamada; Katsuji Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

7.  Ets2-dependent stromal regulation of mouse mammary tumors.

Authors:  Albert K Man; Lawrence J T Young; John A Tynan; Jacqueline Lesperance; Mikala Egeblad; Zena Werb; Craig A Hauser; William J Muller; Robert D Cardiff; Robert G Oshima
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

8.  Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.

Authors:  X M Liu; L G Wang; W Kreis; D R Budman; L M Adams
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

9.  ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function.

Authors:  Daniel R Christie; Faheem M Shaikh; John A Lucas; John A Lucas; Susan L Bellis
Journal:  J Ovarian Res       Date:  2008-10-01       Impact factor: 4.234

10.  The function of APC/CCdh1 in cell cycle and beyond.

Authors:  Min Li; Pumin Zhang
Journal:  Cell Div       Date:  2009-01-19       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.